Lexaria Bioscience (LEXX) Competitors $2.09 -0.07 (-3.24%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends LEXX vs. CRDL, MCRB, VTYX, CGEN, IXHL, ADVM, CHRS, TELO, CRDF, and SKYEShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Cardiol Therapeutics (CRDL), Seres Therapeutics (MCRB), Ventyx Biosciences (VTYX), Compugen (CGEN), Incannex Healthcare (IXHL), Adverum Biotechnologies (ADVM), Coherus BioSciences (CHRS), Telomir Pharmaceuticals (TELO), Cardiff Oncology (CRDF), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Cardiol Therapeutics Seres Therapeutics Ventyx Biosciences Compugen Incannex Healthcare Adverum Biotechnologies Coherus BioSciences Telomir Pharmaceuticals Cardiff Oncology Skye Bioscience Cardiol Therapeutics (NASDAQ:CRDL) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation. Which has more volatility and risk, CRDL or LEXX? Cardiol Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Is CRDL or LEXX more profitable? Lexaria Bioscience's return on equity of -88.39% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cardiol TherapeuticsN/A -194.40% -129.07% Lexaria Bioscience N/A -88.39%-84.05% Does the MarketBeat Community favor CRDL or LEXX? Cardiol Therapeutics received 19 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 62.16% of users gave Cardiol Therapeutics an outperform vote. CompanyUnderperformOutperformCardiol TherapeuticsOutperform Votes2362.16% Underperform Votes1437.84% Lexaria BioscienceOutperform Votes4100.00% Underperform VotesNo Votes Does the media prefer CRDL or LEXX? In the previous week, Cardiol Therapeutics had 20 more articles in the media than Lexaria Bioscience. MarketBeat recorded 21 mentions for Cardiol Therapeutics and 1 mentions for Lexaria Bioscience. Cardiol Therapeutics' average media sentiment score of 0.32 beat Lexaria Bioscience's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardiol Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, CRDL or LEXX? Lexaria Bioscience has higher revenue and earnings than Cardiol Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardiol Therapeutics$60K2,203.20-$20.84M-$0.39-4.15Lexaria Bioscience$230K143.76-$6.66M-$0.44-4.75 Do institutionals and insiders believe in CRDL or LEXX? 12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Comparatively, 7.6% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate CRDL or LEXX? Cardiol Therapeutics currently has a consensus price target of $8.75, indicating a potential upside of 440.12%. Lexaria Bioscience has a consensus price target of $11.00, indicating a potential upside of 426.32%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cardiol Therapeutics is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCardiol Therapeutics beats Lexaria Bioscience on 10 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.06M$6.59B$5.21B$8.85BDividend YieldN/A8.14%5.53%4.08%P/E Ratio-4.756.9584.1515.74Price / Sales143.76359.321,248.6188.25Price / CashN/A53.8240.9736.92Price / Book6.3310.617.206.55Net Income-$6.66M$153.27M$119.63M$226.22M7 Day Performance3.98%3.97%2.12%3.77%1 Month Performance-22.59%-6.72%-2.43%4.64%1 Year Performance58.33%33.26%34.55%29.21% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience1.5254 of 5 stars$2.09-3.2%$11.00+426.3%+58.3%$33.06M$230,000.00-4.757CRDLCardiol Therapeutics2.7672 of 5 stars$1.62+2.5%$8.75+440.1%+99.2%$132.19M$60,000.00-4.0420Analyst ForecastAnalyst RevisionNews CoverageGap UpMCRBSeres Therapeutics3.605 of 5 stars$0.77+5.5%$5.08+561.4%-31.4%$131.23M$126.33M-3.28233Analyst UpgradeVTYXVentyx Biosciences2.5868 of 5 stars$1.85+6.9%$10.00+440.5%-21.9%$130.81MN/A-0.8173CGENCompugen3.2131 of 5 stars$1.41-2.8%$4.00+183.7%+117.4%$125.83M$33.46M72.5068Positive NewsIXHLIncannex Healthcare1.1425 of 5 stars$1.98+0.5%N/A+115.2%$125.71M$10,000.00-1.413ADVMAdverum Biotechnologies4.1212 of 5 stars$6.04+5.0%$27.83+360.8%-28.1%$125.64M$1M-0.97190Analyst ForecastNews CoverageCHRSCoherus BioSciences3.7507 of 5 stars$1.09-0.9%$6.13+461.9%-46.0%$125.58M$257.24M-14.00246TELOTelomir PharmaceuticalsN/A$4.24-5.1%N/AN/A$125.55MN/A0.001Analyst RevisionNews CoverageGap UpCRDFCardiff Oncology1.0894 of 5 stars$2.45-2.0%$9.33+281.0%+105.9%$125.27M$490,000.000.0020SKYESkye Bioscience1.264 of 5 stars$4.12-1.2%$18.67+353.1%+171.1%$125.00MN/A0.0011Insider Trade Related Companies and Tools Related Companies CRDL Competitors MCRB Competitors VTYX Competitors CGEN Competitors IXHL Competitors ADVM Competitors CHRS Competitors TELO Competitors CRDF Competitors SKYE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LEXX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
